Sharp, part of UDG Healthcare plc

sharpservices.com

Sharp works across the world to create unique commercial and clinical packaging solutions for the pharmaceutical and biotechnology industry. We are made up of two dynamic international divisions, Sharp Packaging Solutions and Sharp Clinical Services. Together our 1,600-strong team works from state-of-the-art facilities in the United States, United Kingdom, Belgium and the Netherlands. We’ve built an exceptional global reputation for the design, serialisation and production of innovative, cost-effective compliance packaging for even the most complex products.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy, Industrial Impact

EDITAS MEDICINE ANNOUNCES PUBLICATION IN NATURE BIOTECHNOLOGY OF COMPREHENSIVE SLEEK GENE EDITING TECHNOLOGY DATA

Globenewswire | May 02, 2023

news image

Editas Medicine, Inc. a clinical stage genome editing company, announced that the journal Nature Biotechnology published the comprehensive data from a study of the proprietary SLEEK gene editing technology. Despite major progress in achieving gene disruption with CRISPR-Cas gene editing technologies, efficient knock-in of transgenes continues to be a significant challenge for the gene editing field. To solve this challenge, SLEEK was developed to enable high knock-in efficiency ...

Read More

Industrial Impact, Diagnostics

KITE AND ARCELLX CLOSE DEAL TO DEVELOP AND MARKET LATE-STAGE CLINICAL CART-DDBCMA

Kite Pharma and Arcellx | January 31, 2023

news image

On January 30, 2023, Kite and Arcellx, Inc. informed that they have completed their previously-announced global strategic collaboration to co-develop and co-market CART-ddBCMA. CART-ddBCMA is Arcellx's lead late-stage candidate for treating patients with relapsed or refractory multiple myeloma. For the majority of patients, multiple myeloma is an incurable disease; hence, there is a continuing demand for treatments that are not only effective but also secure and e...

Read More

Medical

TGEN SELECTS MEMVERGE TO ACCELERATE IDIOPATHIC PULMONARY FIBROSIS RESEARCH DISCOVERY WITH BIG MEMORY TECHNOLOGY

MemVerge | March 21, 2022

news image

MemVerge™, the pioneers of Big Memory software, today announced that TGen, the Translational Genomics Research Institute, an affiliate of City of Hope, has selected MemVerge Memory Machine Big Memory virtualization software to accelerate time to discovery for Idiopathic Pulmonary Fibrosis (IPF), a disease which affects 100,000 people annually in the U.S. Using MemVerge technology, TGen is able to dramatically speed analytical processing by nearly 36% for single-cell RNA sequencing. ...

Read More

Industrial Impact

ADM FURTHER EXPANDS MICROBIAL SCIENCE AND TECHNOLOGY INNOVATION CAPABILITIES WITH INVESTMENT IN PRECISION FERMENTATION LEADER ACIES BIO

ADM | October 22, 2021

news image

ADM a global leader in nutrition and agricultural origination and processing, annoThis investment will help ADM more quickly advance projects in the field of precision microbial fermentation by leveraging Acies Bio’s extensive microbial capabilities and contract manufacturing services. “Microbial technology is unlocking disruptive opportunities in sustainable agriculture, sustainable materials and fuels, and alternative proteins, We’re prope...

Read More
news image

Cell and Gene Therapy, Industrial Impact

EDITAS MEDICINE ANNOUNCES PUBLICATION IN NATURE BIOTECHNOLOGY OF COMPREHENSIVE SLEEK GENE EDITING TECHNOLOGY DATA

Globenewswire | May 02, 2023

Editas Medicine, Inc. a clinical stage genome editing company, announced that the journal Nature Biotechnology published the comprehensive data from a study of the proprietary SLEEK gene editing technology. Despite major progress in achieving gene disruption with CRISPR-Cas gene editing technologies, efficient knock-in of transgenes continues to be a significant challenge for the gene editing field. To solve this challenge, SLEEK was developed to enable high knock-in efficiency ...

Read More
news image

Industrial Impact, Diagnostics

KITE AND ARCELLX CLOSE DEAL TO DEVELOP AND MARKET LATE-STAGE CLINICAL CART-DDBCMA

Kite Pharma and Arcellx | January 31, 2023

On January 30, 2023, Kite and Arcellx, Inc. informed that they have completed their previously-announced global strategic collaboration to co-develop and co-market CART-ddBCMA. CART-ddBCMA is Arcellx's lead late-stage candidate for treating patients with relapsed or refractory multiple myeloma. For the majority of patients, multiple myeloma is an incurable disease; hence, there is a continuing demand for treatments that are not only effective but also secure and e...

Read More
news image

Medical

TGEN SELECTS MEMVERGE TO ACCELERATE IDIOPATHIC PULMONARY FIBROSIS RESEARCH DISCOVERY WITH BIG MEMORY TECHNOLOGY

MemVerge | March 21, 2022

MemVerge™, the pioneers of Big Memory software, today announced that TGen, the Translational Genomics Research Institute, an affiliate of City of Hope, has selected MemVerge Memory Machine Big Memory virtualization software to accelerate time to discovery for Idiopathic Pulmonary Fibrosis (IPF), a disease which affects 100,000 people annually in the U.S. Using MemVerge technology, TGen is able to dramatically speed analytical processing by nearly 36% for single-cell RNA sequencing. ...

Read More
news image

Industrial Impact

ADM FURTHER EXPANDS MICROBIAL SCIENCE AND TECHNOLOGY INNOVATION CAPABILITIES WITH INVESTMENT IN PRECISION FERMENTATION LEADER ACIES BIO

ADM | October 22, 2021

ADM a global leader in nutrition and agricultural origination and processing, annoThis investment will help ADM more quickly advance projects in the field of precision microbial fermentation by leveraging Acies Bio’s extensive microbial capabilities and contract manufacturing services. “Microbial technology is unlocking disruptive opportunities in sustainable agriculture, sustainable materials and fuels, and alternative proteins, We’re prope...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us